Novel Therapies Targeting Kidney Disease


Latest Press Releases
Press releases
  • 08 Jan 2025

    25% of patients recruited in Guard Therapeutics phase 2b POINTER study

    Read more
  • 04 Dec 2024  ·  Regulatory information

    Guard Therapeutics presents the Nomination Committee for 2025

    Read more
  • 16 Oct 2024

    First patient in Europe dosed in the clinical phase 2b POINTER study

    Read more
  • 24 Sep 2024  ·  Regulatory information

    Guard Therapeutics announces outcome in rights issue

    Read more
Show more
In focus
  • 17 Oct 2024 / Presentation

    Guard presents at Redeye Theme "Cardiovascular & Metabolic Diseases Event 2024"

    Read more
  • 23 Sep 2024 / Presentation

    CEO Tobias Agervald appears on BiotechTV

    Read more
  • 19 Sep 2024 / Presentation

    Presentation at Pareto Securities' 15th Annual Healthcare Conference

    Read more
  • 30 Jan 2024 / Presentation

    Guard Therapeutics R&D update January 30, 2024

    Read more
Show more
Upcoming events
  • 20 Feb 2025

    Year-end report 2024

    Read more
  • 14 Apr 2025

    Annual Report 2024 (approximate date)

    Read more
  • 05 May 2025

    Interim report January-March 2025

    Read more
  • 05 May 2025

    Annual General Meeting 2025

    Read more
Event calendar/Financial calendar